Nitromide (3,5-Dinitrobenzamide)
(Synonyms: 3,5-二硝基苯甲酰胺,3,5-Dinitrobenzamide) 目录号 : GC33953
Nitromide (3,5-Dinitrobenzamide) 是一种抗寄生虫剂。
Cas No.:121-81-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nitromide is an anti-parasitic agent.
| Cas No. | 121-81-3 | SDF | |
| 别名 | 3,5-二硝基苯甲酰胺,3,5-Dinitrobenzamide | ||
| Canonical SMILES | O=C(N)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 | ||
| 分子式 | C7H5N3O5 | 分子量 | 211.13 |
| 溶解度 | DMSO : ≥ 2.2 mg/mL (10.42 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.7364 mL | 23.6821 mL | 47.3642 mL |
| 5 mM | 0.9473 mL | 4.7364 mL | 9.4728 mL |
| 10 mM | 0.4736 mL | 2.3682 mL | 4.7364 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Decomposition of 3,5-Dinitrobenzamide in aqueous solution during UV/H2O2 and UV/TiO2 oxidation processes
Environ Sci Pollut Res Int 2017 Feb;24(6):5360-5369.PMID:28013465DOI:10.1007/s11356-016-8245-1.
3,5-Dinitrobenzamide has been widely used as a feed additive to control coccidiosis in poultry, and part of the added 3,5-Dinitrobenzamide is excreted into wastewater and surface water. The removal of 3,5-Dinitrobenzamide from wastewater and surface water has not been reported in previous studies. Highly reactive hydroxyl radicals from UV/hydrogen peroxide (H2O2) and UV/titanium dioxide (TiO2) advanced oxidation processes (AOPs) can decompose organic contaminants efficiently. In this study, the decomposition of 3,5-Dinitrobenzamide in aqueous solution during UV/H2O2 and UV/TiO2 oxidation processes was investigated. The decomposition of 3,5-Dinitrobenzamide fits well with a fluence-based pseudo-first-order kinetics model. The decomposition in both two oxidation processes was affected by solution pH, and was inhibited under alkaline conditions. Inorganic anions such as NO3-, Cl-, SO42-, HCO3-, and CO32- inhibited the degradation of 3,5-Dinitrobenzamide during the UV/H2O2 and UV/TiO2 oxidation processes. After complete decomposition in both oxidation processes, approximately 50% of 3,5-Dinitrobenzamide was decomposed into organic intermediates, and the rest was mineralized to CO2, H2O, and other inorganic anions. Ions such as NH4+, NO3-, and NO2- were released into aqueous solution during the degradation. The primary decomposition products of 3,5-Dinitrobenzamide were identified using time-of-flight mass spectrometry (LCMS-IT-TOF). Based on these products and ions release, a possible decomposition pathway of 3,5-Dinitrobenzamide in both UV/H2O2 and UV/TiO2 processes was proposed.
Design, synthesis and antimycobacterial activity of 3,5-Dinitrobenzamide derivatives containing fused ring moieties
Bioorg Med Chem Lett 2018 Sep 15;28(17):2945-2948.PMID:30006066DOI:10.1016/j.bmcl.2018.07.005.
We report herein the design, synthesis and antimycobacterial activity of 3,5-Dinitrobenzamide derivatives containing fused ring moieties. Results reveal that many of the target compounds have considerable in vitro antitubercular activity. Especially, N-((2-(4-fluorophenyl)/N-((2-(3-fluorobenzyl)-1,2,3,4-tetrahydroisoquilin-6-yl)methyl)-3,5-dinitrobenzamides 18a and 20e exhibit potent MIC values of 0.056-0.078 μg/mL against both drug-sensitive Mycobacterium tuberculosis (MTB) H37Rv strain and two clinically isolated multidrug-resistant MTB (MDR-MTB) strains, opening a new direction for further SAR studies.
Identification of the major urinary and fecal metabolites of 3,5-Dinitrobenzamide in chickens and rats
Chemosphere 1999 Apr;38(8):1757-62.PMID:10101847DOI:10.1016/s0045-6535(98)00392-0.
Colostomized chickens given oral doses of 3,5-Dinitrobenzamide (Nitromide) cleared Nitromide predominantly through the urine (58% of dose) and feces (21% of dose). Rats cleared 52% of Nitromide via urinary excretion and 44% via feces. Major urinary metabolites for both chickens and rats include: 3-amino-5-nitrobenzamide, 3-acetamido-5-nitrobenzamide, 3-acetamide-5-aminobenzamide, and 3,5-diacetamidobenzamide. The major fecal metabolite in chickens was 3-acetamido-5-nitrobenzamide (67% of fecal 14C) and 3-acetamido-5-aminobenzamide in rats (approximately 50%).
The metabolic fate of nitromide in the rat. I. Metabolism and excretion
Xenobiotica 1980 Apr;10(4):289-97.PMID:7415210DOI:10.3109/00498258009033757.
1. Following oral administration of Nitromide (3,5-Dinitrobenzamide) to rats, 67.9% of the dose was excreted in urine and 32.6% in the faeces in 96 h. Significant biliary excretion of nitromide metabolites also occurred, although no evidence of enterohepatic cycling was obtained. Direct secretion of nitromide metabolites into the gastro-intestinal lumen via the mucosa was detected in surgically modified rats. 2. Six faecal, six urinary and three biliary metabolites, all of which were in a reduced form (as monoamines, diamines and their conjugates) were detected following oral administration. 3. The blood of these animals contained reduced metabolites only, as early as 1 h after oral or intraperitoneal administration of nitromide.
Metabolism of nitromide in the rat. II. Sites of nitro-reduction
Xenobiotica 1980 Apr;10(4):299-305.PMID:7415211DOI:10.3109/00498258009033758.
1. Nitromide (3,5-Dinitrobenzamide) is reduced to monoamino- and diamino-metabolites in vitro on anaerobic incubation with rat intestinal microflora. This conversion is suppressed by the antibiotics neomycin, tetracycline and bacitracin. 2. Nitromide is also in part reduced to monoamino but not diamino metabolites when incubated aerobically with homogenates of rat liver. 3. Pretreatment of rats with the antibiotics did not decrease their ability to form monoamino metabolites from nitromide, although formation of diamino metabolites was suppressed. 4. An antibiotic regime shown to suppress the methaemoglobinaemia resulting from the administration of nitrobenzene did not significantly reduce the methaemoglobinaemia resulting from the administration of nitromide.